Spinocerebellar Degenerations: Clinical Trials

254 trials for Spinocerebellar Degenerations, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

132 completed, 40 recruiting, 25 unknown, 21 active not recruiting. 71 Phase 2, 58 Not applicable, 35 Phase 1, 32 Phase 3, 4 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 271Completed 48, Recruiting 6, Not yet recruiting 4, Unknown 4, Withdrawn 4, Terminated 3, Active not recruiting 2
Not applicable58Completed 30, Recruiting 10, Unknown 9, Active not recruiting 3, Not yet recruiting 3, Withdrawn 2, Enrolling by invitation 1
Phase 135Completed 17, Recruiting 5, Active not recruiting 4, Unknown 3, Not yet recruiting 2, Terminated 2, Withdrawn 2
Phase 332Completed 19, Active not recruiting 5, Not yet recruiting 3, Terminated 3, Recruiting 2
Phase 44Completed 4
Early Phase 12Completed 2

Follow Spinocerebellar Degenerations: new trials by email Literature Review of Spinocerebellar Degenerations trials Research Report on Spinocerebellar Degenerations

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
Intravenous infusion, Intrathecal injection, umbilical cord mesenchymal stem cell - Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2
Phase 2Not yet recruitingSclnow Biotechnology Co., Ltd.452026-12-312026-04-23
Multi-Modal Digital Monitoring of Disease Symptoms in Spinocerebellar Ataxia
Spinocerebellar Ataxia (SCA)
Not yet recruitingBioSensics252026-12-152026-10-01
GV101 for Friedreich's Ataxia (FA) Treatment
GV101, Placebo - Friedreich's Ataxia
Phase 2Not yet recruitingGraviton Bioscience Corporation482026-11-012026-10-15
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
Nomlabofusp, Placebo - Friedreich Ataxia, Friedreich's Ataxia
Phase 3RecruitingLarimar Therapeutics, Inc.1502026-10-262026-10-09
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
Omaveloxolone - Friedreich Ataxia
RecruitingBiogen102026-10-262026-07-10
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults
ATI-105, Placebo - Friedreich Ataxia, Cardiomyopathies
Phase 1Not yet recruitingAdjuvia Therapeutics, Inc.602026-10-262026-10-09
A Study to Learn More About Friedrich's Ataxia in People Living in the Gulf Cooperation Council (GCC) Region of the World
Friedreich's Ataxia
Not yet recruitingBiogen402026-10-152026-10-21
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
Pembrolizumab, Porustobart - Colon Cancer
Phase 2RecruitingSolstice Oncology, Inc.1002026-09-302026-10-22
Rare Disease Registry Database for Movement Disorders in Southern Anhui Province
Motor Neuron Diseases, Spinocerebellar Ataxias
RecruitingFirst Affiliated Hospital of Wannan Medical College1802026-09-302026-10-23
Pivotal Study of N-acetyl-L-leucine for CACNA1A
N-Acetyl-L-Leucine, Placebo - CACNA1A, Spinocerebellar Ataxia Type 6
Phase 3RecruitingIntraBio Inc602026-08-172026-09-08
Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)
Vatiquinone - Friedreich's Ataxia
Phase 3Not yet recruitingPTC Therapeutics1202026-08-152026-08-14
Optimizing Parameters of Transcranial Temporal Interference Stimulation for Spinocerebellar Ataxia Type 3
Transcranial Temporal Interference Stimulation (tTIS) - Spinocerebellar Ataxia Type 3
Not applicableNot yet recruitingFirst Affiliated Hospital of Fujian Medical University242026-08-072026-09-01
FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC
FOLFIRI + bevacizumab + QL1706, FOLFIRI + bevacizumab - Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Phase 3Not yet recruitingSun Yat-sen University2702026-07-302026-07-27
Digital Outcome Assessment Using AI Active Gaming and Motion Capture in Friedreich Ataxia
Laboratory validation session (VSimulator), Home-based active gaming assessment - Friedreich Ataxia
Not yet recruitingUniversity of Exeter402026-07-302026-07-28
Cardiac Output and Fatigue in Friedreich's Ataxia
Aerobic Exercise - Friedreich's Ataxia
Not applicableRecruitingScott Barbuto302026-07-152026-09-22
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
LX2006, Usual Care - Friedreich Ataxia, Cardiomyopathy, Secondary
Phase 2RecruitingLexeo Therapeutics262026-06-252026-09-02
Interposed Nucleus aDBS for Ataxia
Deep Brain Stimulation - Spinocerebellar Ataxia (SCA), Spinocerebellar Ataxia Type 6
Not applicableRecruitingUniversity of Florida52026-06-022026-07-20
SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer
short-course radiaotherapy, long-course chemoradiaothearpy, Capecitabine - Locally Advanced Rectal Cancer (LARC), MSS (Microsatellite Stable)
Phase 3Not yet recruitingFudan University6122026-05-012026-04-24
Deep Brain Stimulation for Spinocerebellar Ataxia
Deep Brain Stimulation (DBS) - Spinocerebellar Ataxia (SCA), Spinocerebellar Ataxia Type 6
Not applicableRecruitingUniversity of California, San Francisco52026-04-272026-07-13
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
IDE574, Fulvestrant injection - ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC)
Phase 1RecruitingIDEAYA Biosciences1602026-03-172026-06-16

Showing 20 of 254. Sign in to see all of them.

Narrower conditions

Friedreich Ataxia (110)  ·  Spinocerebellar Ataxias (92)  ·  Ataxia (33)  ·  Machado-Joseph Disease (32)  ·  Cerebellar Ataxia (19)  ·  Colorectal Neoplasms (12)  ·  Cardiomyopathies (10)  ·  Rare Diseases (9)  ·  Multiple System Atrophy (7)  ·  Neurodegenerative Diseases (6)  ·  Genetic Diseases, Inborn (5)  ·  Huntington Disease (5)  ·  Movement Disorders (5)  ·  Parkinson Disease (5)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (254)  ·  Heredodegenerative Disorders, Nervous System (254)  ·  Spinal Cord Diseases (254)  ·  Brain Diseases (253)  ·  Central Nervous System Diseases (252)  ·  Nervous System Diseases (251)  ·  Cerebellar Diseases (250)  ·  Genetic Diseases, Inborn (249)  ·  Neurodegenerative Diseases (248)  ·  Neurologic Manifestations (126)  ·  Dyskinesias (124)  ·  Nutritional and Metabolic Diseases (113)  ·  Metabolic Diseases (111)  ·  Mitochondrial Diseases (106)

Interventions

alpha-tocotrienol quinone (7)  ·  idebenone (7)  ·  omaveloxolone (6)  ·  pembrolizumab (6)  ·  Blood Specimen Collection (5)  ·  Transcranial Magnetic Stimulation (4)  ·  interferon gamma-1b (4)  ·  Bevacizumab (3)  ·  Deep Brain Stimulation (3)  ·  Fluorouracil (3)  ·  Immunoglobulins, Intravenous (3)  ·  Leucovorin (3)  ·  Lithium Carbonate (3)  ·  Magnetic Resonance Spectroscopy (3)  ·  Nivolumab (3)

Sponsors

Kissei Pharmaceutical Co., Ltd. (9)  ·  Larimar Therapeutics, Inc. (8)  ·  Biogen (7)  ·  University of South Florida (7)  ·  Children's Hospital of Philadelphia (6)  ·  Institut National de la Santé Et de la Recherche Médicale, France (6)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (6)  ·  PTC Therapeutics (6)  ·  University of Florida (6)  ·  Assistance Publique - Hôpitaux de Paris (5)  ·  Chang Gung University (5)  ·  Hospital de Clinicas de Porto Alegre (5)  ·  Columbia University (4)  ·  Design Therapeutics, Inc. (4)  ·  IRCCS Eugenio Medea (4)

Countries

United States (123)  ·  France (40)  ·  Italy (34)  ·  Germany (27)  ·  Spain (22)  ·  Australia (20)  ·  Canada (16)  ·  China (16)  ·  Austria (15)  ·  Brazil (15)  ·  United Kingdom (14)  ·  Belgium (13)  ·  Netherlands (12)  ·  Taiwan (12)  ·  Japan (11)

Top investigators

Theresa Zesiewicz, MD (5)  ·  David Lynch, MD, PhD (4)  ·  Alberto Benussi, MD (3)  ·  Barbara Borroni, MD (3)  ·  David Lynch, MD (3)  ·  Magdy Shenouda, M.D. (3)  ·  Susan Perlman, MD (3)  ·  Alessandro Filla, MD (2)  ·  Alexandra Durr, MD, PhD (2)  ·  Arnold Munnich, M.D. (2)  ·  Carlos Gordon, Prof. (2)  ·  Cherie Marvel, PhD (2)

Results publications

PMID 40739200, PMID 17562928, PMID 21779958, PMID 24780882, PMID 31937586, PMID 34115419, PMID 42307907, PMID 15313841, PMID 15365159, PMID 15496622, PMID 16055926, PMID 16193476, PMID 16267188, PMID 16501573, PMID 16849828, PMID 16900450, PMID 17098887, PMID 17597328, PMID 17605047, PMID 17826341, PMID 17957230, PMID 18378516, PMID 18853458, PMID 19387333, PMID 20090835, PMID 20599042, PMID 20697044, PMID 21392622, PMID 22003934, PMID 22491195, PMID 22633670, PMID 22744651, PMID 23151076, PMID 23707147, PMID 24399647, PMID 25434572, PMID 25449974, PMID 25773989, PMID 26297649, PMID 26321318, PMID 26377379, PMID 26417459, PMID 26480849, PMID 26644294, PMID 26943780, PMID 27389519, PMID 27839651, PMID 27848087, PMID 28168524, PMID 28365204

NIH funding

2025 (5), 2017 (2), 2019 (2), 2008 (1), R01DC016275 (1), R01NS072248 (1), R21NS085491 (1), R21NS094946 (1), R21NS125546 (1), R61HL151355 (1), U01NS106670 (1), UL1TR000064 (1)